PHOSPHODIESTERASE-5 INHIBITORS, SEXUAL HABITS OF MEN AND TREATMENT COMPLIANCE
- Авторлар: Borisov V.V.1, Borisov VV1
-
Мекемелер:
- Шығарылым: № 6 (2011)
- Беттер: 53-58
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278847
- ID: 278847
Дәйексөз келтіру
Толық мәтін
Аннотация
The article presents information about the problem of male health at the multidisciplinary aspect, male and female sexuality, and the frequency of male sexual disorders depending on age, androgen levels, and concomitant cardiovascular diseases, psycho-neurological and endocrine factors. The modern wide range of application of phosphodiesterase-5 inhibitors, especially Viagra, for modeling and improvement of erections, restoration of sexual function in general in patients with different diseases is considered. The advantages of Viagra in the group of inhibitors of phosphodiesterase-5, and the prospects for its further application are presented.
Әдебиет тізімі
- NIH Consensus Development Panel on Impotence. JAMA 1993;270(1):83-90.
- Montague DK, Barada JH, Belker AM, et al. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. The American Urological Association. J Urol 1996;156:2007-11.
- Carson CC, et al. Presented at: Annual Meeting of the American Urological Association; May 25-30, 2002; Orlando, Fla.
- Aytac IA, McKinlay JB, Krane RJ, et al. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-6.
- Padma-Nathan H, et al Minimal time to successful intercourse after sildenafil citrate: results of a randomized double-blind, placebo-controlled trial. Urology 2003;62:400--03.
- Инструкция по медицинскому применению препарата Виагра. Одобрена Росздравнадзором от 12.08.2009, с изменениями от 11.02.2010.
- Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998;10:69-74.
- Розничные цены аптек Москвы, доступные на: www.medlux.ru
- Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl 2007;9(1):134-41.
- Тарасов Н.И., Бавильский В.Ф., Матыгин А.С. Длительная монотерапия силденафила цитратом при различных формах эректильной дисфункции // Клиническая фармакология и терапия 2009. № 18(2). C. 34-7.
- Moncada I, Jara J, Subira D, et al. Efficacy of sildenafil citrate at 12 hours after dosing: reexploring the therapeutic window. Eur Urol 2004;46(3):357-60.
- Eropean Association of Urology. Guidelines on Erectile Dysfunction, Update March 2009:18.
- Jae-Seung Paik, et al. The efficacy and safety of udenafil, a newselective phosphodiesterase Type 5 inhibitor, in patients with erectile dysfunction. J Sex Med 2008;5:946-53.
- Seftel AD, et al. A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia. International Journal of Impotence Research 2005;17:455-61.
- Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil, and tadalafil review of the literature. Eur J Med Res 2002;7:435-46.
Қосымша файлдар
